Wegovy 'journey' videos: what TikTok skips about semaglutide

What did @_autumnoleary actually say?

She said she just got approved to start Wegovy and wanted to walk viewers through "the process of getting Wegovy prescribed to you through doctors visits, talking with insurance, filling out a pre-authorization." Her framing is that this process is poorly understood and took her significant research to figure out. She is not making medical claims. She is describing a bureaucratic and clinical navigation process, which is a meaningfully different thing.

To her credit, she does not claim Wegovy is easy to get, cheap, or that anyone can qualify. She frames it as something that requires steps, documentation, and patience. That is an accurate framing. What she has not yet gotten into, at least in this clip, are the actual eligibility criteria, what a pre-authorization requires medically, or what happens when insurance denies coverage. Those gaps matter.

Does the science back this up?

The process she describes is real and well-documented in the literature. Getting semaglutide approved through insurance is genuinely difficult for most patients, and the barriers are not just bureaucratic.

A 2023 analysis published in JAMA Health Forum (Dusetzina et al., 2023) found that GLP-1 receptor agonists like semaglutide remain inaccessible to a large share of commercially insured patients due to prior authorization requirements, step therapy mandates, and high out-of-pocket costs. The average list price for Wegovy sits around $1,350 per month without coverage. Even with insurance, step therapy often requires patients to fail on other weight loss interventions first before a plan will approve semaglutide.

Her description of pre-authorization as a necessary step is accurate. Prior authorization for Wegovy typically requires documented BMI of 30 or higher, or 27 with at least one weight-related comorbidity, consistent with the FDA-approved indication confirmed in the STEP trials (Wilding et al., 2021, New England Journal of Medicine).

What did they get wrong (or right)?

She got the framing right. The process is genuinely confusing, and the information gap she describes is real. Most patients do not know what prior authorization means, what documentation their prescriber needs to submit, or how long the approval process takes. Research from the Obesity Medicine Association has consistently noted that patients and even some providers underestimate the administrative burden involved.

What is missing, and this is worth flagging, is any mention of eligibility criteria. Not everyone who wants Wegovy qualifies for it medically or will be approved by their insurer. The video could give viewers the impression that getting approved is primarily a paperwork problem you can research your way through. For some patients, the answer is simply that their BMI does not meet the threshold, or their plan excludes anti-obesity medications entirely. The Kaiser Family Foundation estimated in 2023 that roughly 25 percent of large employer plans exclude GLP-1s for obesity outright, regardless of documentation.

What should you actually know?

If you are trying to get Wegovy covered, there are a few things worth understanding before you start the process. First, your prescriber matters enormously. A provider experienced with prior authorizations for anti-obesity medications will know how to document your case in a way that meets insurer criteria. A general practitioner who rarely prescribes semaglutide may not.

Second, prior authorization denial is common and appealable. The first denial is not the final answer. A 2022 study in Health Affairs (Sachs et al.) found that appeal success rates for specialty medications vary widely but can exceed 50 percent when patients submit additional clinical documentation.

Third, Novo Nordisk offers a savings program called the Wegovy Savings Card that can reduce costs for eligible commercially insured patients, but it does not apply to Medicare or Medicaid enrollees. There are also patient assistance programs for those who qualify based on income. None of this is simple, which is exactly what she said, and she is not wrong about that.